BIOMAT Database Logo BIOMAT Database Logo

Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. 1996

H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Department of Internal Medicine I, University of Vienna Medical School, Austria.

OBJECTIVE To measure serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease (PAOD) Fontaine stages IIb, III, and IV. METHODS The study population comprised 38 patients (20 men and 18 women) with stage IV PAOD, 11 patients (six men and five women) with stage III PAOD, 18 patients (10 men and eight women) with stage IIb PAOD, and 23 patients (10 men and 13 women) with deep vein thrombosis. Fifteen normal subjects (matched for risk factors) and 10 patients (five men and five women) without PAOD served as controls. Serum samples were obtained at admission and serum laminin and angiogenin concentrations were measured using an enzyme linked immunosorbent assay. RESULTS Patients with stage IV PAOD had higher serum laminin (mean +/- SEM; 826 +/- 97 ng/ml) and angiogenin concentrations (467 +/- 26 pg/ml) than normal subjects (laminin: 379 +/- 21 ng/ml; angiogenin: 358 +/- 16 pg/ml) and patients without PAOD (laminin: 277 +/- 34 ng/ml; angiogenin: 406 +/- 25 pg/ml). A significant correlation was found between angiogenin and laminin and between serum laminin and fibrinogen concentrations in patients with stage IV disease. CONCLUSIONS Raised laminin and angiogenin concentrations may be indicators of endothelial damage caused by reduced vascular perfusion or compensatory revascularisation, or both.

UI MeSH Term Description Entries
D007797 Laminin Large, noncollagenous glycoprotein with antigenic properties. It is localized in the basement membrane lamina lucida and functions to bind epithelial cells to the basement membrane. Evidence suggests that the protein plays a role in tumor invasion. Merosin,Glycoprotein GP-2,Laminin M,Laminin M Chain,Chain, Laminin M,Glycoprotein GP 2,M Chain, Laminin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001157 Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency. Arterial Obstructive Diseases,Arterial Occlusion,Arterial Obstructive Disease,Arterial Occlusions,Arterial Occlusive Disease,Disease, Arterial Obstructive,Disease, Arterial Occlusive,Obstructive Disease, Arterial,Occlusion, Arterial,Occlusive Disease, Arterial
D012259 Ribonuclease, Pancreatic An enzyme that catalyzes the endonucleolytic cleavage of pancreatic ribonucleic acids to 3'-phosphomono- and oligonucleotides ending in cytidylic or uridylic acids with 2',3'-cyclic phosphate intermediates. EC 3.1.27.5. RNase A,Ribonuclease A,Pancreatic RNase,RNase I,Ribonuclease (Pancreatic),Ribonuclease I,Pancreatic Ribonuclease,RNase, Pancreatic

Related Publications

H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease.
July 1999, The Journal of clinical endocrinology and metabolism,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Haemodilution in patients with peripheral arterial occlusive disease.
January 1992, International angiology : a journal of the International Union of Angiology,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Hyperhomocysteinaemia in patients with peripheral arterial occlusive disease.
August 2001, Clinical chemistry and laboratory medicine,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Hyperuricemia in patients with peripheral arterial occlusive disease.
April 1974, Angiology,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease.
December 2001, Clinical pharmacology and therapeutics,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Evaluation of serum adipokines in peripheral arterial occlusive disease.
January 2012, Mediators of inflammation,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Increased laminin concentrations in serum in hyperthyroidism.
July 1989, Clinical chemistry,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Correlation between mesenteric fat thickness and serum apolipoproteins in patients with peripheral arterial occlusive disease.
October 2012, Lipids in health and disease,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
Increased risk of peripheral arterial occlusive disease in patients with Bell's palsy using population data.
January 2017, PloS one,
H Burgmann, and U Hollenstein, and T Maca, and K Zedwitz-Liebenstein, and F Thalhammer, and R Koppensteiner, and H Ehringer, and W Graninger
[Peripheral arterial occlusive disease]
January 2016, La Revue du praticien,
Copied contents to your clipboard!